ARTICLE | Clinical News
Hematopoietic stem cells regulatory update
December 3, 2001 8:00 AM UTC
The FDA granted orphan drug designation to NEXL's hematopoeitic stem cells to treat chronic granulomatous disease (CGD). The product is in Phase III testing. ...